Latest news

20.Nov 20

+200 attendees joined our webcast today
Thank you to the +200 interested attendees that joined our live webcast today...

19.Nov 20

Invitation to Scandion Oncology A/S live webcast on 20 November 2020
Invitation to Scandion Oncology A/S live webcast on 20 November 2020 We ha...

19.Nov 20

CEO Bo Rode Hansen interviewed by MedWatch about rights issue
CEO Bo Rode Hansen has been intervi...

06.Nov 20

CEO Bo Rode Hansen presents at InvestorUgen
Scandion Oncology´s President and CEO, Bo Rode Hansen will be giving a live v...

06.Oct 20

Scandion Oncology presents at Erik Penser Bank on Oct 7, 2020
Scandion Oncology will present tomorrow at 13:45-14.25 at the “Temadag Cancer...

01.Oct 20

CEO Bo Rode Hansen has been interviewed about his visions
CEO Bo Rode Hansen has been interviewed by BioStock about his visions for Sca...

21.Sep 20

Interview with our new CEO, Bo Rode Hansen, and our comming CSO, Nils Brünner
Our new CEO, Bo Rode Hansen, and ou...

16.Sep 20

Interview with Scandion Oncology about new CEO
Scandion Oncology has just announced in a Press Release that Bo Rode Hansen h...

21.Aug 20

Live event with CEO Nils Brünner
On ...

06.Aug 20

Strong first half of 2020 - summarized by BioStock
BioStock has summarized the main achievement in Scandion oncology from the ve...

05.Aug 20

Sum up of the first clincal data with SCO-101 and FOLFIRI
BioStock has made a very nice sum up of the first clincal results with SCO-10...

03.Aug 20

Press release from July 31st in Swedish
We have had many Swedish investors that asked if the English version of the p...

03.Aug 20

Live event with CEO Nils Brünner
On August 2nd, 2020, CEO Nils Brünn...

29.Jun 20

CEO Nils Brünner is interviewed by BioStock BioStock Studio
CEO Nils Brünner is interviewed by ...

26.Jun 20

Børsen article can be read here for free
We are very happy to provide the opportunity to non-subscribers of Børsen to ...

25.Jun 20

Scandion Oncology is discussed in Nordnets Investeringspodcasten
Very nice discussion about Scandion Oncology in #Nordnet hosted by Per Hansen...

24.Jun 20

Free acess to MedWatch interview with Bo Rode Hansen about the board position in Scandion Oncology
The MedWacth interview with Bo Rode Hansen regarding his board position in Sc...

24.Jun 20

Medicon Valley Alliance interview with CEO Nils Brünner
Medicon Valley Alliance has interviewed CEO Nils Brünner about the preclinica...

24.Jun 20

CEO Nils Brünner and CEO Per Norlén (Alligator Bioscience) comments on the preclinical collaboration
CEO Nils Brünner (Scandion Oncology) and CEO Per Norlén (Alligator Bioscience...

23.Jun 20

Børsen has interviewed CEO Nils Brünner about the potential of Scandion Oncology
Børsen has interviewed CEO Nils Brünner about the history and potential of Sc...

22.Jun 20

Interview with CEO Nils Brünner and CEO Ole Thastrup (2cureX)
BioStock has interviewed CEO Nils B...

22.Jun 20

Today Scandion Oncology presents at the AACR Virtual Annual Meeting II
As previously announced, AACR has published a Scandion Oncology abstract for ...

19.Jun 20

Bo Rode Hansen has joined the Board of Scandion Oncology
Very pleased that Bo Rode Hansen recently joined the board of Scandion Oncolo...

15.Jun 20

Live Q&A with CEO Nils Brünner and Chairman Peter Høngaard
Today Scandion Oncology will present in a LIVE Q&A. From Scandion Onco...

10.Jun 20

CEO Nils Brünner interviewed by BioStock about the positive development
CEO Nils Brünner has been interviewed about the milestones and the positive d...

05.Jun 20

MedWatch interview with CEO Nils Brünner on the collaboration between Scandion Oncology and Alligator Bioscience
MedWatch has interwied CEO Nils Brü...

02.Jun 20

Exposure biomarker in clinical Phase II trial?
Q: Could you explain more about the exposure biomarker mentioned in your Pres...

28.May 20

BioStock interview with CEO Nils Brünner on the international competition and potential for Scandion Oncology.
BioStock has interviewed CEO Nils Brünner about the international competition...

15.May 20

AACR has published an abstract on pre-clinical effects of SCO-101 in colorectal cancer
We are happy to announce that AACR has published a Scandion Oncology abstract...

24.Apr 20

Publication of PCT application on anti microbial infection
The Scandion Oncology PCT application "WO2020079051 - COMPOUNDS FOR TREATMENT...

17.Apr 20

BioStock interview with CSO Jan Stenvang on publication on predictive biomarkers
BioStock has interviewed CSO Jan Stenvang about a new publication on irinotec...

08.Apr 20

Publication of PCT application on SRPK1
The Scandion Oncology PCT application “WO2020049139 - UREA DERIVATIVES FOR US...

06.Apr 20

Patient recruitment status updated
The recruitment for the ongoing Phase II clinical trial (ClinicalTrials.gov I...

27.Mar 20

BioStock interview with CSO Jan Stenvang on SCO-101 and docetaxel
BioStock has interviewed CSO Jan Sten...

18.Mar 20

EU publication on SCANRESIST project
EU has published a "Results in Brief" article on the CORDIS website on our SC...

13.Mar 20

Interview with CEO Nils Brünner and CSO Jan Stenvang in BioStock
BioStock has interviewed CEO Nils Brünner and CSO Jan Stenvang about the rece...

27.Feb 20

CEO Nils Brünner presents at the Life Science Investor Conference on March 4

Økonomisk Ugebrev Life Science inviterer til årets første Investorkonfere...

03.Feb 20

CEO Presentation from Aktiespararna Investor Day
CEO Nils Brünner presented at Aktispararna Investor meeting on January, 28th,...

31.Jan 20

CEO Nils Brünner will present at the Life Science Investor conference held by Økonomisk Ugebrev

Økonomisk Ugebrev Life Science inviterer til årets første Investorkonfere...

27.Jan 20

CEO Nils Brünner will present tomorrow at Aktiespararna
CEO...

17.Dec 19

CEO Nils Brünner is interviewed by Børsen
In Børsen today CEO Nils Brünner is interviewed to the Life Science Denmark s...

22.Nov 19

BioStock article about Scandion Oncology
BioStock has published an article about Scandion Oncology. The focus is on th...

22.Nov 19

Interview with CEO Nils Brünner in BioStock
BioStock has intervied CEO Nils Brünner. The interview gives a short and and ...

30.Oct 19

Scandion Oncology will present at Sedermeradagen on November 18, 2019, in Stockholm
CEO Nils Brünner will present news from Scandion Oncology at Sedermeradagen i...

04.Oct 19

Peter Høngaard - our new Chairman of the Board - is portrayed and interview by BioStock
The full interview and portray with Peter Høngaard can be read below, or dire...

24.Sep 19

Scandion Oncology CEO Newsletter autumn 2019
Nils Brünner, CEO, has summarized the current activities of Scandion Oncology...

24.Sep 19

Scandion Oncology will present on the Nordic Rise Launch Party
#Scandion Oncology will join the Launch Party of Nordic Rise on Thursday 26. ...

17.Sep 19

Investor Lunch in Copenhagen on Oct 1st
#Scandion Oncology looks very much forward to present at an investor lunch in...

01.Jul 19

BioStock presentation of Scandion Oncology and the ongoing Rights Issue
BioStock has made a nice background about Scandion Oncology and the ongoing R...

27.Jun 19

Unit Rights for shareholders
Dear Investor and current shareholder in Scandion Oncology, As a reminder ...

24.Jun 19

Rights Issue investor presentation in Copenhagen on June 25
CEO Nils Brünner will present Scandion Oncology and the Rights Issue in Copen...

21.Jun 19

Scandion Oncology is now a member of Nordic Rise
Scandion Oncology has joined Nordic Rise, which is a focussed, ambitious and ...

21.Jun 19

Presentation and interview from BioStock Live
CEO Nils Brünner presented Scandion Oncology at the investor meeting "BioStoc...

21.Jun 19

Rights Issue investor presentations next week
CEO Nils Brünner will present Scandion Oncology and the Rights Issue at 4 inv...

13.Jun 19

CEO Nils Brünner presents today at the investor meeting "BioStock Live investerarträff"
CEO Nils Brünner will present today at the investor meeting "BioStock Live in...

03.Jun 19

Watch the presentation from Småbolagsdagen 2019 in Stockholm
CEO Nils Brünner presented at the investor meeting Småbolagsdagen 2019 in Sto...

02.Jun 19

Scandion Oncology presents at the investor meeting Småbolagsdagen 2019 in Stockholm
CEO Nils Brünner will present Scandion Oncology to more than 400 investors in...

21.May 19

Scandion Oncology presentation from Öresundsdagen investor meeting
CEO Nils Brünner presented Scandion Oncology at the Öresundsdagen investor me...

06.May 19

Scandion Oncology will present at Öresundsdagen in Malmö on May 20
This a kind reminder that you can meet Scandion Oncology on Monday 20th in Ma...

01.May 19

Joint investor meeting with 2cureX on April 30
On April 30...

29.Mar 19

Scandion Oncology presented in Berlingske
Today, in Berlingske there is a special issue on "Fremtidens Investeringer". ...

19.Mar 19

Scandion Oncology presentation from Sedermeradagen
CEO Nils Brünner presented the status and the plans for Scandion Oncology at ...

04.Mar 19

Production of SCO-101 is following the plan
Scandion Oncology had on February 28, 2019, a face-to-face meeting with our d...

04.Mar 19

Scandion Oncology will present at Sedermeradagen in Copenhagen on March 12
Sedermeradagen will take place on March 12 at the Marriott Hotel in Copenhage...

01.Mar 19

Scandion Oncology has today moved to new facilities at Symbion
Today Scandion Oncology has moved to new facilities at Symbion (Fruebjergvej ...

02.Jan 19

Strategy meeting in Scandion Oncology
The BoD and management of Scandion Oncology gathered at Karlaby Kro on Dec. 1...

10.Sep 18

Presentation at the 13th Annual EORTC PatoBiology Group Meeting on September 15, 2018 in Hamburg, Germany
CSO Jan Stenvang will present data on SCO-101 and endocrine resistance in br...

10.Sep 18

Presentation at the conference “Response and Resistance in Cancer therapy” on September 10, 2018 in Kent, UK
CEO Nils Brünner will present data on SCO-101 and endocrine resistance in br...

10.Sep 18

Presentation at the conference “Response and Resistance in Cancer therapy” on September 9, 2018 in Kent, UK
CEO Nils Brünner will present data on SCO-101 and chemotherapy resistance at ...

10.Sep 18

Scandion has submitted a patent application regarding a novel mechanism of action for its lead compound SCO-101
Scandion Oncology has discovered a novel mechanism of action for its lead com...

05.Sep 18

Scandion Oncology A/S presents at the MVA Oncology Network Pitch event at Medicon Village, Lund, Sweden, September 5th, 2018
CSO Jan Stenvang will pitch the background and status of Scandion Oncology A/...

16.Aug 18

Thomas Feldthus has joined the Board of Scandion Oncology
Thomas Feldthus has joined the Board of Scandion Oncology. Thomas Feldthus re...

06.Aug 18

Scandion Oncology A/S signs agreement with Sedermera Fondkommission AB regarding an Initial Public Offering at Spotlight Stock Market.

Scandion Oncology A/S hereby announces that an agreement has been signed w...

09.May 18

Scandion Oncology A/S presents at Sedermeradagen, Malmö, Sweden May 15th 2018
Sedermeradagen is an investor day where Scandion Oncology A/S will present to...

24.Apr 18

Scandion Oncology A/S meets with Big Pharma at ”Focus on Cancer Collaboration” at Medicon Village, Lund, Sweden April 24th
CMO Nils Brünner will present the background and status of Scandion Oncology ...

22.Apr 18

InnoBooster grant from Innovation Fund Denmark
Scandion Oncology has been awarded an InnoBoster grant from Innovation Fund D...

22.Apr 18

Presentation at Danish Association for Cancer Research
Scandion Oncology will present data on SCO-101 at the annual meeting “Danish ...

22.Apr 18

Presentation at ESMO GI
Scandion Oncology will present data on SCO-101 at ESMO GI in Barcelona, Spain...

19.Dec 17

Saniona Spin-Out, Scandion Oncology Raises DKK 2 Million and Prepares for a Potential Public Listing
Saniona, a leading biotech company in the field of ion channels, today announ...

20.Nov 17

Abstracts and poster presentations on October 28, 2017
Abstracts and poster presentations on October 28, 2017, at the AACR-NCI-EORTC...

19.Nov 17

Poster presentation on November 1, 2017
Poster presentation on November 1, 2017, at the Biomarker AGORA 2017, Copenha...

Co-funded by the Horizon 2020 programme of the European Union

Co-funded by the COSME programme of the European Union